Acta Scientific Microbiology (ISSN: 2581-3226)

Research Article Volume 6 Issue 8

Study Between Seromarkers (IL-2, IFN-γ and Anti-HBS Titer) and Type 2 Diabetic Subjects with Duration of Diabetes Following Hepatitis B Vaccination

Sujal Kumar Bokshi1* and Ashesh Chowdhury2

1MBBS, MPhil (Immunology), MO in Charge of Pathology and RMO, District Hospital, Narail, Bangladesh

2Professor and Head of Department of Immunology, BIRDEM, Dhaka, Bangladesh

*Corresponding Author: Sujal Kumar Bokshi, MBBS, MPhil (Immunology), MO in Charge of Pathology and RMO, District Hospital, Narail, Bangladesh. Email:

Received: July 03, 2023; Published: July 13, 2023


Background: The immune status is usually hampered in patients with diabetes mellitus. They are more prone to develop infections. In diabetic patients’ a higher prevalence of hepatitis B virus infection is also observed, which leads to more severe complications. The Hepatitis B vaccine is used to prevent hepatitis B virus infection, but there remains uncertainty about vaccine response in diabetic patients. The global pandemic of diabetes principally involved type 2 diabetes.

Aim of the Study: To find out the immune responses of diabetic patients to the hepatitis B vaccine, as measured by seromarkers, may help identify potential factors influencing vaccine efficacy and inform targeted interventions to improve immunization outcomes in this population.

Methods: This was a cohort study where 33 diabetic patients were included as the experimental group and 34 non-diabetic healthy persons were included as a control group. They all were serum HBsAg, anti-HBs and anti-HBc test negative. The experimental and control groups were similar statistically regarding age, gender, serum bilirubin, ALT and serum creatinine. All the participants were vaccinated with the hepatitis B vaccine following a 0, 1, and 6-months schedule. The vaccine responses in the diabetic and non-diabetic groups were compared depending on zero markers (anti-HBs titer, IL-2 and IFN-γ) levels following vaccination. In the case of type 2 diabetic subjects, the seromarkers were also correlated with the duration of diabetes.

Result: The correlation between the duration of type 2 diabetes and serum IFN-γ allowing hepatitis B vaccination is shown in figure 1. Here the correlation coefficient (r) was -0.105, and the p-value was >0.05. So, the correlation between the duration of type 2 diabetes and serum IFN-γ following hepatitis B vaccination was negative but insignificant. The correlation between the duration of type 2 diabetes and serum IFN-γ following hepatitis B vaccination was also negative but insignificant because the r-value was -0.139 and the p-value was >0.05.

Conclusion: The serum value of IFN-γ was significantly lower in the diabetic subjects than in non-diabetic subjects following hepatitis B vaccination. The percentage of seroprotective titer was nearly the same for diabetic and non-diabetic subjects. Serum IL-2 and anti-HBs titer showed no significant difference between diabetic and non-diabetic subjects. The correlations of serum anti-HBs titer, IFN-γ and IL-2 with the duration of diabetes were found negative, but the correlations were not significant.

 Keywords: Seromarkers; Hepatitis B Vaccine; Type 2 Diabetic Patients


  1. Wild S., et al. “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030”. Diabetes Care5 (2004): 1047-1053.
  2. Demir M., et al. “The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients”. European Journal of Gastroenterology and Hepatology7 (2008): 668-673.
  3. Waters RS., et al. “The effects of interleukin-2 on immune response regulation”. Mathematical Medicine and Biology: a Journal of the IMA1 (2018): 79-119.
  4. Kak G., et al. “Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases”. Biomolecular Concepts1 (2018): 64-79.
  5. Hyer RN and Janssen RS. “Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years”. Vaccine39 (2019): 5854-5861.
  6. Jaroszewicz J., et al. “Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective”. Journal of Hepatology4 (2010): 514-522.
  7. Ljubic S., et al. “Pulmonary infections in diabetes mellitus”. Diabetologia Croatica4 (2004): 115-124.
  8. Catrina EL., et al. “Soft tissue infections: risk factors in diabetes mellitus patients”. Maedica A Journal of Clinical Medicine4 (2009).
  9. Ronald A and Ludwig E. “Urinary tract infections in adults with diabetes”. International Journal of Antimicrobial Agents4 (2001): 287-292.
  10. Eckhard M., et al. “Fungal foot infections in patients with diabetes mellitus–results of two independent investigations”. Mycoses 50 (2007): 14-19.
  11. Burke A Cunha. Diabetic food infections” (2009).
  12. Davila JA., et al. “Diabetes increases the risk of hepatocellular carcinoma in the United States: a population-based case control study”. Gut4 (2005): 533-539.
  13. Amarapurkar DN., et al. “Impact of diabetes mellitus on outcome of HCC”. Annals of Hepatology2 (2008): 148-151.
  14. El-Serag HB., et al. “Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma”. Gastroenterology2 (2004): 460-468.
  15. Garcia-Compean D., et al. “Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management”. World Journal of Gastroenterology: WJG3 (2009): 280.
  16. Alexiewicz JM., et al. “Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function”. Annals of Internal Medicine12 (1995): 919-924.
  17. Delamaire M., et al. “Impaired leucocyte functions in diabetic patients”. Diabetic Medicine1 (1997): 29-34.
  18. Delespesse G., et al. “Cell-mediated immunity in diabetes mellitus”. Clinical and Experimental Immunology4 (1974): 461.
  19. Alba-Loureiro TC., et al. “Neutrophil function and metabolism in individuals with diabetes mellitus”. Brazilian Journal of Medical and Biological Research 40 (2007): 1037-1044.
  20. Rostami N., et al. “Comparison of immune response to hepatitis B vaccine between term and preterm infants at birth” (2006).
  21. Awofeso N. “Hepatitis B vaccination in prisons”. Bulletin of the World Health Organization7 (2002): 569-574.


Citation: Sujal Kumar Bokshi and Ashesh Chowdhury. “Study Between Seromarkers (IL-2, IFN-γ and Anti-HBS Titer) and Type 2 Diabetic Subjects with Duration of Diabetes Following Hepatitis B Vaccination". Acta Scientific Microbiology 6.8 (2023): 19-25.


Copyright: © 2023 Sujal Kumar Bokshi and Ashesh Chowdhury. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2023.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US